10-QPeriod: Q1 FY2013

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2013

Filed April 30, 2013For Securities:SYK

Summary

Stryker Corporation's Q1 2013 filing reveals a modest 1.3% year-over-year increase in net sales, reaching $2.19 billion. However, net earnings saw a significant decline of 13.1% to $304 million, translating to a diluted EPS of $0.79, down from $0.91 in the prior year. This decrease in profitability was influenced by higher operating expenses, particularly in Selling, General, and Administrative (SG&A) which rose 11.8%, and Research, Development, and Engineering (R&D) which increased 15.2%. Additionally, significant charges related to the Rejuvenate and ABG II hip recall ($32 million) and regulatory matters ($30 million) impacted the bottom line. Operationally, the company demonstrated robust cash flow generation from operating activities, significantly improving to $236 million from $35 million in the prior year, partly due to effective working capital management. Investing activities were heavily impacted by the $600 million acquisition of Trauson Holdings Company Limited, aimed at strengthening the Reconstructive segment and expanding presence in emerging markets. Financing activities saw substantial debt issuance ($1 billion) to fund general corporate purposes and significant share repurchases ($250 million), including an Accelerated Share Repurchase (ASR) program.

Financial Highlights

51 data points
Beta

Revenue

$2.19B

67.4% Gross Margin

Net Income

$304.00M

13.9% Net Margin

EPS (Diluted)

$0.79

Total Assets

$14.09B

Cash & Equivalents

$1.91B

Free Cash Flow

$187.00M

Financial Statements
Beta
Revenue$2.19B
Cost of Revenue$713.00M
Gross Profit$1.48B
R&D Expenses$129.00M
SG&A Expenses$916.00M
Operating Expenses$1.09B
Operating Income$386.00M
Net Income$304.00M
EPS (Basic)$0.80
EPS (Diluted)$0.79
Shares Outstanding (Basic)379.70M
Shares Outstanding (Diluted)383.00M

Key Highlights

  • 1Net sales grew slightly by 1.3% to $2.19 billion, while net earnings decreased by 13.1% to $304 million.
  • 2Diluted EPS declined to $0.79 from $0.91 in the prior year, impacted by increased operating expenses and specific charges.
  • 3Operating cash flow significantly improved to $236 million from $35 million, showcasing enhanced operational efficiency.
  • 4Acquisition of Trauson Holdings for $600 million marked a key strategic move to bolster the Reconstructive segment and emerging market presence.
  • 5The company raised $1 billion in long-term debt and repurchased $250 million in common stock, indicating active capital management.
  • 6Significant charges were recognized for the Rejuvenate and ABG II hip recall ($32M) and regulatory matters ($30M), impacting profitability.
  • 7Research, Development, and Engineering expenses increased by 15.2%, signaling continued investment in innovation.

Frequently Asked Questions

The decrease in net earnings was primarily driven by a significant increase in operating expenses, particularly Selling, General, and Administrative (SG&A) expenses which rose 11.8%, and Research, Development, and Engineering (R&D) expenses which grew 15.2%. Additionally, the company incurred substantial charges related to the voluntary recall of its Rejuvenate and ABG II modular-neck hip stems ($32 million) and significant regulatory matters ($30 million), which further impacted profitability.

The acquisition of Trauson Holdings for $600 million significantly impacted investing activities, representing the largest use of cash in this category for the quarter. This strategic move is expected to enhance Stryker's Reconstructive segment, broaden its presence in China, and expand its reach into the value segment of emerging markets. The acquisition is reflected in the consolidated financial statements prospectively from its March 1, 2013, closing date.

Stryker demonstrated a strong improvement in operating cash flow, generating $236 million compared to $35 million in the prior year, indicating effective working capital management. This cash, along with proceeds from debt issuance, was utilized for strategic investments, including the acquisition of Trauson, and significant share repurchases totaling $250 million, which included an Accelerated Share Repurchase (ASR) program.

The report highlights ongoing legal and regulatory matters, including investigations by the DOJ and SEC, and product liability lawsuits stemming from the hip stem recall. The estimated costs for the hip recall are substantial, ranging from $230 million to $430 million before insurance recoveries, and the ultimate resolution could materially affect financial position and results of operations. Other risks include the potential impact of foreign currency fluctuations and the ongoing restructuring efforts related to workforce reduction.